Trials / Recruiting
RecruitingNCT07403552
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (estimated)
- Sponsor
- Ensho Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the pharmacokinetics, safety, and tolerability of NSHO-101 in Healthy Participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NSHO-101 | Dose form - tablet Route of administration - oral Regimen / Treatment period - QD for 14 days |
Timeline
- Start date
- 2026-01-31
- Primary completion
- 2026-03-01
- Completion
- 2026-06-01
- First posted
- 2026-02-11
- Last updated
- 2026-02-11
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07403552. Inclusion in this directory is not an endorsement.